U.S. court invalidates patent on Bristol hepatitis B drug
A U.S. federal court has invalidated the U.S. patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.
"We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said. She said the company is considering whether to appeal the ruling by the U.S. District Court in Delaware.
Bristol-Myers had filed suit against Israeli drugmaker Teva in 2010 to block introduction of its generic form of Baraclude. Hortas said the drug's chemical patent lapses in February 2015, but declined to comment on whether U.S. regulators might allow Teva's generic onto the market before then.
Teva officials could not immediately be reached for comment.
ISI Group analyst Mark Schoenebaum said the U.S. Food and Drug Administration would have to approve Teva's marketing application before its generic could be introduced, and that it was unclear when the FDA might act.
Schoenebaum said Baraclude is expected to have U.S. sales this year of about $260 million. Even if the Teva generic arrives this year and hurts Baraclude's U.S. sales, he said Bristol-Myers will probably not need to lower its current full-year profit forecast.
Shares of Bristol-Myers were down 0.6 percent at $36.69 on the New York Stock Exchange on Tuesday morning. Teva shares were down 0.4 percent in Tel Aviv.
Baraclude generates $250+ million USD per year for BMS. The drug is patented for 10 years so thats rougly $2.5 billion USD for BMS.
It would be in thier best interest to develop better drugs for the Hepatitis B market and have them available after the patent expires. Considering thier is a lot of potential to treat people, drug manufacturers should jump on the Hepatitis B market.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.